MONROVIA, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, a privately held company that provides specialty formulations of human milk for the immunological and nutritional needs of premature and critically ill infants, announced today that it has raised over $5 million in private venture funding for its series B prime financing round from a combination of existing investors, new investors, and several high profile angel investors.
